
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience Inc. has made significant strides in its clinical-stage biopharmaceutical development, particularly with ALTO-207 (CTC-501), which has shown improvements in tolerability compared to pramipexole, allowing for higher doses and a fast titration regimen that could enhance treatment benefits for depressive symptoms. Additionally, the new transdermal formulation of ALTO-101 has exhibited an improved safety profile and favorable pharmacokinetics, which are encouraging indicators for its ongoing Phase 2 study in CIAS patients. These advancements position Alto Neuroscience favorably within its target market, reflecting a strong potential for positive clinical outcomes and market acceptance of its personalized treatment approaches.
Bears say
Alto Neuroscience Inc has faced significant pressure on its stock since its IPO in 2024, primarily due to the failure of its lead asset, ALTO-100, in a Phase 2b study for major depressive disorder. Additionally, the ongoing Phase 2b study in bipolar depression is viewed as a high-risk program with a low probability of success, further dampening investor sentiment. Compounding these challenges, negative data related to ALTO-300 has raised concerns about the company’s overall pipeline and future growth potential.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares